⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29897491 | 0.97 | — | — | |
| SCHEMBL17351802 | 0.69 | — | — | |
| SCHEMBL31266330 | 0.67 | — | — | |
| SCHEMBL21798206 | 0.62 | — | — | |
| SCHEMBL4208544 | 0.61 | CA1 (0.38) | — | |
| SCHEMBL5507786 | 0.61 | — | — | |
| SCHEMBL25084136 | 0.60 | — | — | |
| SCHEMBL3809324 | 0.60 | — | — | |
| SCHEMBL4185099 | 0.60 | — | — | |
| SCHEMBL19411556 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661923-B1 | N-HETEROCYCLIC COMPOUNDS AS OREXIN 2 AGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-15 | — | — | EP | claimed |
| US-20260109711-A1 | MACROCYCLIC SULFONAMIDE MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4626546-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-10-08 | — | — | EP | disclosed |
| US-20250289828-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND RELATED USES | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2025-09-18 | — | — | US | disclosed |
| US-20250236629-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND RELATED USES | OXFORD FINANCE LLC | 2025-07-24 | — | — | US | disclosed |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | NIMBUS CLOTHO, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2025072673-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS IRE 1 INHIBITORS | AL22.02.01, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-4486748-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND RELATED USES | Centessa Pharmaceuticals (UK) Limited (GB) | 2025-01-08 | — | — | EP | disclosed |
| CN-119110802-A | Heterocyclic derivatives substituted with a middle or macrocyclic benzyl group and related uses | 森特萨制药(英国)有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-12071434-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-27 | — | — | US | disclosed |
| US-20130115190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-09 | — | — | US | disclosed |
| US-20130115190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-09 | — | — | US | disclosed |
| US-20130115190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-09 | — | — | US | disclosed |
| WO-2012151195-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012151195-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120213729-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20120213729-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| WO-2012024373-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20090047244-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS I | IDENIX PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009014730-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |